

**THE PREVALENCE OF CELIAC DISEASE IN
PATIENTS FULFILLING ROME III CRITERIA
FOR IRRITABLE BOWEL SYNDROME**

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Internal Medicine*

Submitted by

George Magdy Hanna

M.B.B.Ch

Faculty of Medicine-Cairo University

Under supervision of

Prof. Saied Abdelnabi Shalaby

Professor of Internal Medicine & Gastroenterology

Faculty of Medicine -Ain Shams University

Dr. Moataz Mohamed Saied

Assistant Professor of Internal Medicine & Gastroenterology

Faculty of Medicine - Ain Shams University

Dr. Wesam Ahmed Ibrahim

Assistant Professor of Internal Medicine & Gastroenterology

Faculty of Medicine - Ain Shams University

Ain Shams University

2013



*First thanks to **ALLAH** to whom I relate any success in achieving any work in my life.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Saied Abdelnabi Shalaby**, Professor of Internal Medicine & Gastroenterology for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Dr. Moataz Mohamed Saied**, Assistant Professor of Internal Medicine & Gastroenterology for his sincere efforts and fruitful encouragement.*

*I am deeply thankful to **Dr. Wesam Ahmed Ibrahim**, Assistant Professor of Internal Medicine & Gastroenterology for his great help, outstanding support, active participation and guidance.*

George Magdy

List of Contents

Title	Page No.
Introduction.....	1
Aim of the Work	3
Review of Literature	
▪ Celiac Disease.....	4
▪ Irritable Bowel Syndrome (IBS)	31
▪ Overlap between IBS and Celiac Disease	76
Patients and Methods	79
Results	89
Discussion.....	103
Conclusion and Recommendations.....	112
References	114
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Ig, immunoglobulin; ELISA, enzyme-linked immunosorbent assay; IFA, immunofluorescence assay.....	23
Table (2):	ROME III and ROME II criteria	59
Table (3):	Comparison between IBS with tTG positive and IBS with tTG negative as regards sex.	90
Table (4):	Comparison between IBS with tTG positive and IBS with tTG negative as regards age.....	91
Table (5):	Comparison between IBS with tTG positive and IBS with tTG negative as regards pain duration.....	92
Table (6):	Comparison between IBS with tTG positive and IBS with tTG negative as regards CBC.....	93
Table (7):	Comparison between IBS with tTG positive and IBS with tTG negative as regards INR, PTT	94
Table (8):	Comparison between IBS with tTG positive and IBS with tTG negative as regards ESR.	96
Table (9):	Comparison between IBS with tTG positive and IBS with tTG negative as regards liver function	97
Table (10):	Comparison between IBS with tTG positive and IBS with tTG negative as regards renal function.....	98

List of Tables (Cont...)

Table No.	Title	Page No.
Table (11):	Comparison between IBS with tTG positive and IBS with tTG negative as regards Na and K.....	98
Table (12):	Comparison between IBS with tTG positive and IBS with tTG negative as regards RBS.	99
Table (13):	Comparison between IBS with tTG positive and IBS with tTG negative as regards TTG.....	100
Table (14):	Correlation between tTG and study parameters.	100

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Pathogenesis of Celiac Disease.....	13
Figure (2):	Dermatitis herpetiformis	20
Figure (3):	Endoscopic and biopsy findings in patients with and without celiac disease (A) High-definition endoscopic photo of normal small intestine.....	25
Figure (4):	This photomicrograph from a biopsy sample shows an intestinal lining that's been severely damaged by gluten.	26
Figure (5):	Comparison between IBS with tTG positive and IBS with tTG negative as regards sex.	90
Figure (6):	Comparison between IBS with tTG positive and IBS with tTG negative as regards age	91
Figure (7):	Comparison between IBS with tTG positive and IBS with tTG negative as regards pain duration	92
Figure (8):	Comparison between IBS with tTG positive and IBS with tTG negative as regards INR.....	95
Figure (9):	Comparison between IBS with tTG positive and IBS with tTG negative as regards PTT.	95
Figure (10):	Comparison between IBS with tTG positive and IBS with tTG negative as regards ESR.....	96

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (11):	Comparison between IBS with tTG positive and IBS with tTG negative as regards RBS	99
Figure (12):	Comparison between IBS with tTG positive and IBS with tTG negative as regards TTG	100
Figure (13):	Correlation between tTG and total protein.	102
Figure (14):	Correlation between tTG and serum albumin.	102

List of Abbreviations

Fig. No.	Title	Page No.
<i>ACG</i>	<i>American College of Gastroenterology</i>	
<i>ACTH</i>	<i>Adrenocorticotropin hormone</i>	
<i>ATA</i>	<i>Anti-tissue transeglutaminase antibodies</i>	
<i>CBC</i>	<i>Complete blood count</i>	
<i>CBT</i>	<i>Cognitive behavioural therapy</i>	
<i>CCK</i>	<i>Cholecystokinin</i>	
<i>CD</i>	<i>Celiac disease</i>	
<i>CI</i>	<i>Confidence interval</i>	
<i>CRF</i>	<i>Corticotrophin releasing factor</i>	
<i>CRH</i>	<i>Corticotrophin releasing hormone</i>	
<i>DNIC</i>	<i>Diffuse noxious inhibitory control</i>	
<i>DZ</i>	<i>Dizygotic</i>	
<i>EGG</i>	<i>Electrogastrography</i>	
<i>EMA</i>	<i>Endomysial antibodies</i>	
<i>ESR</i>	<i>Erythrocyte sedimentation rate</i>	
<i>FBC</i>	<i>Full blood count</i>	
<i>FBD</i>	<i>Functional bowel disorders</i>	
<i>FDA</i>	<i>Food and Drug Administration</i>	

List of Abbreviations (Cont...)

Fig. No.	Title	Page No.
<i>fMRI</i>	<i>Functional magnetic resonance imaging</i>	
<i>fMRI</i>	<i>Functional magnetic resonance imaging</i>	
<i>GFD</i>	<i>Glutin Free diet</i>	
<i>GI</i>	<i>Gastrointestinal tract</i>	
<i>GWAS</i>	<i>Genome-wide association studies (GWAS)</i>	
<i>HAPCs</i>	<i>High amplitude propagating contractions</i>	
<i>HLA</i>	<i>Human leukocyte antigen</i>	
<i>HPA</i>	<i>Hypothalamo-pituitary-adrenal</i>	
<i>IBS</i>	<i>Irritable bowel syndrome</i>	
<i>IBS-C</i>	<i>Constipation predominant IBS</i>	
<i>IBS-D</i>	<i>Diarrhea predominant IBS</i>	
<i>IBS-M</i>	<i>IBS with mixed bowel pattern</i>	
<i>IgA</i>	<i>Immunoglobulin A</i>	
<i>IL-10</i>	<i>Interleukin-10</i>	
<i>MMC</i>	<i>Migrating motor complex</i>	
<i>MZ</i>	<i>Monozygotic</i>	
<i>NNT</i>	<i>number needed to treat</i>	
<i>PET</i>	<i>Positron emission tomography</i>	

List of Abbreviations (Cont...)

Fig. No.	Title	Page No.
<i>PIT</i>	<i>Psychodynamic interpersonal therapy</i>	
<i>PTH</i>	<i>Parathormone hormone</i>	
<i>RBS</i>	<i>Random blood sugar</i>	
<i>RCT</i>	<i>Randomised controlled trial</i>	
<i>Serum Alb</i>	<i>Serum Albumin</i>	
<i>Serum Cr</i>	<i>Serum creatinine</i>	
<i>SNPs</i>	<i>Single-nucleotide polymorphisms</i>	
<i>SSRI</i>	<i>Selective serotonin reuptake inhibitor</i>	
<i>T. Prot</i>	<i>Total protein</i>	
<i>TNFα</i>	<i>Tumour necrosis factor α</i>	
<i>tTG</i>	<i>Tissue Transglutaminase</i>	
<i>WBC</i>	<i>White blood cells count</i>	
<i>5-HT</i>	<i>5-hydroxytryptamine receptor</i>	

INTRODUCTION

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of specific organic pathology. It is the most commonly diagnosed gastrointestinal condition and accounts for approximately 30 percent of all referrals to gastroenterologist (*Drossman, 2002*).

Its prevalence varies in human communities and in the majority of all studies; it is more prevalent in females than males (*Horwitz et al., 2001*). IBS is a disorder of the youth with most new cases appearing prior to the age of 45 (*Drossman, 2002*).

The ROME III criteria system was developed to classify the functional gastrointestinal disorders based on clinical symptoms. Each disorder has its own set of criteria. The Rome III criteria for irritable bowel syndrome (IBS) is as follows: Symptoms of recurrent abdominal pain or discomfort and a marked change in bowel habit for at least six months, with symptoms experienced on at least three days of at least three months. Two or more of the following must apply:

- Pain is relieved by a bowel movement.

- Onset of pain is related to a change in frequency of stool.
- Onset of pain is related to a change in the appearance of stool.

(Longstreth et al., 2006)

Celiac disease (CD) is known as gluten-sensitive enteropathy or celiac sprue, defined as a permanent intolerance to ingested gluten (the storage protein components of wheat, barley, and rye). The clinical presentation of CD can vary from a classical malabsorption syndrome to more subtle atypical gastrointestinal manifestations (similar to irritable bowel syndrome) or extra intestinal presentations (for example, infertility, osteoporosis, and iron-deficiency anemia). It can be clinically silent often detected by serologic screening of those subjects at risk, with villous atrophy in the intestine. An individual may have a latent predisposition to CD, which is defined by a positive serology in the absence of villous atrophy on the small intestine *(Alberto et al., 2007)*.

The most sensitive antibody tests for the diagnosis of celiac disease are of the IgA class. The available tests include those for antigliadin antibodies, connective-tissue antibodies (antireticulin and antiendomysial antibodies), and antibodies directed against tissue transglutaminase, the enzyme responsible for the deamidation of gliadin in the lamina propria *(Rostom et al., 2005)*.

AIM OF THE WORK

To study the prevalence of Celiac disease (CD) disease in Egyptian patients with clinically diagnosed irritable bowel syndrome (according to ROME III criteria) (with predominant diarrhea).

CELIAC DISEASE

Celiac disease was first described by Samuel Gee in 1888, although a similar description of a chronic malabsorptive disorder by Aretaeus of Cappadocia (now Turkey) dates back to the second century. Gee described the classic features of celiac disease as diarrhea, lassitude, and failure to thrive; he believed that the regulation of food was the main part of the treatment and noted that the disease was not age-specific. Since this time, much has been learned about the diagnosis and treatment of celiac disease (*Fasano et al., 2001*).

Definition:

Celiac disease is a genetically determined autoimmune-like disorder induced by gluten, the storage protein of wheat and similar proteins found in barley and rye (*Green et al., 2003*).

The autoimmune component of the disease is evidenced by the development of autoantibodies to the endomysium, reticulin, and tissue transglutaminase (*Alaedini et al., 2005*).

Epidemiology:

Celiac disease occurs in both children and adults throughout the western world at rates of 1%, with some groups reporting rates five-fold greater in infants compared with adults (*Mariné et al., 2011*).

Recent prevalence studies have begun to focus on populations in which data have been previously lacking. Celiac disease is more prevalent than first thought in Eastern Europe and Asia, with as many as 1% of Latvians and 1.44% of north Indians testing positive for celiac antibodies on routine screening (*Leja et al., 2011*).

This rise is largely attributed to increased awareness, greater education and a resultant 16% annual increase in serological testing for celiac disease (*Mariné et al., 2011*).

Pathophysiology:

Celiac disease is the end result of 3 processes that culminate in intestinal mucosal damage:

- 1- Genetic predisposition
- 2- Environmental factors
- 3- Immunologically based inflammation (*Greco et al., 1997*).

Celiac disease may be the result of an evolutionary collision between the cultivation of wheat and the human